본문 바로가기
KERD
논문KCI 등재

The Expression of c-myc, bcl-2 and p53 Proteins in Adenocarcinomas of Lung

Jinyoung Yoo|Ji Han Jung|Chang Suk Kang|Hyun Joo Choi|강석진Seok Jin Kang
대한암학회 (Korean Cancer Association)|2004.04|Cancer Research and Treatment|제36권 제2호|pp. 146-150

1

조회

0

다운로드

0

인용

0

참고문헌

주제분류의학일반

초록

Abstract

Purpose: c-myc, bcl-2 and p53 are known to regulate apoptosis. There has been growing interest in analyzing their contribution to the pathogenesis and prognosis in a variety of human cancers. This study was undertaken to investigate the expression of these proteins in pulmonary adenocarcinomas and to determine their relationship with clinicopathologic parameters and survival. Materials and Methods: Archival tumor tissues from 61 patients with adenocarcinoma of lung were analyzed by immunohistochemistry for the expression of c-myc, bcl-2 and p53 proteins. Clinical information was obtained through the computerized retrospect database from the tumor registry. Results: Of 61 patients, 32 were men and 29 women with the median age 63 years. 4 had stage I disease, 2 had stage II disease and 55 had stage III disease. The expression of c-myc protein was identified in 13% (8/61) tumors, bcl-2 protein was detected in 1.6% tumors (1/61) and p53 was detected in 77% (47/71) tumors. The association of the expression of c-myc, bcl-2 and p53 was not detected. The survival time was longer in patients expressing c-myc protein than in patients without the c-myc protein expression (p=.045). Neither bcl-2 nor p53 showed the correlation to clinicopathologic variables. Conclusion: Our data suggest the involvement of p53 alteration in the pathogenesis of lung adenocarcinoma. The c-myc expression in some tumors indicates that c-myc alone may not contribute critically to the development and/or the progression of these tumors. It, however, correlated to the survival time, suggesting the c-myc expression as a favorable prognostic factor possibly through the apoptosis pathway.(Cancer Res Treat. 2004;36:146-150)

참고문헌 (25)

  1. "Apoptosis. Its significancein cancer and cancer therapy.", 73, pp.2013~2026 (1994)
  2. "Apoptosis", 67, pp.205~208 (1993)
  3. "c-myc suppresses the tumorigenicity of lungcancer cells and down-regulates vascular endothelial growthfactor expression", 60, pp.143~149 (2000)
  4. "The myc family of oncogenesand their presence and importance in small-cell lungcarcinoma and other tumor types", 13, pp.1372~1385 (1993)
  5. "Myc family oncogeneamplification in tumor cell lines established from small celllung cancer patients and its relationship to clinical status andcourse", 79, pp.1629~1634 (1987)
  6. "C-myc oncoprotein in bronchial carcinoma:expressionin all major morphological types", 10, pp.623~628 (1990)
  7. "Prognostic value of ERBB-1,VEGF, cyclin A, FOS, JUN, and MYC in patients withsquamous cell carcinomas", 77, pp.663~669 (1998)
  8. "Wild-type p53 induces apoptosis of myeloid leukaemiccells that is inhibited by interleukin-6", 352, pp.345~347 (1991)
  9. "Inductionof apoptosis by wild-type p53 in a human colon tumorderivedcell line", 89, pp.4495~4499 (1992)
  10. "Wild-type but not mutant p53 can repress transcription inhibitionin vitro by interfering with the binding of basal transcriptionfactors to the TATA motif", 8, pp.1183~1193 (1993)
  11. "c-myctransactivates the p53 promoter through a required downstreamCACGTG motif", 4, pp.57~65 (1993)
  12. "The bcl-2oncogene:apoptosis and neoplasia", 136, pp.307~12 (1993)
  13. "Apoptoticcell death induced by c-myc is inhibited by bcl-2", 359, pp.552~554 (1992)
  14. "Apoptosis occurs independentlyof bcl-2 and p53 over-expression in non-small celllung carcinoma", 29, pp.45~50 (1996)
  15. "bcl-2 protein innon-small cell lung carcinoma", 329, pp.690~694 (1993)
  16. "bcl-2 and prognosis innon-small cell lung carcinoma", 330, pp.1757~1758 (1994)
  17. "Absence of prognostic significance of bcl-2immunopositivity in non-small cell lung cancer:Analysis of427 cases", 28, pp.1079~1082 (1997)
  18. "Pathology of the lungs" (2000), ChurchillLivingstone
  19. "E-Cadherin expressionand p53 alterations in soft tissue sarcomas:a possible role inepithelial differentiation", 33, pp.343~349 (2001)
  20. "Control of c-myc regulation innormal and neoplastic cells", 56, pp.1~48 (1991)
  21. "The molecular genetics of human lungcancer", 2, pp.461~9 (1989)
  22. "Oncoprotein (c-myc, c-erbB1,c-erbB2, c-fos) and suppressor gene product (p53) expressionin squamous cell carcinomas of the lung. Clinical and biologicalcorrelations.", (12), pp.11~20 (1992)
  23. "c-myc oncogene expression in colorectal cancer", 59, pp.1289~1295 (1987)
  24. "The clinicalsignificance of flow cytometric c-myc oncoprotein quantitationin testicular cancer", 53, pp.331~337 (1986)
  25. "bcl-2 initiates a new category of oncogenes:regulators of cell death", 80, pp.879~886 (1992)

이 간행물의 다른 논문 (7건)

Oxaliplatin: Is It a New Standard Weapon for Colorectal Cancer?Si-Young Kimpp. 91-92Molecular Epidemiology of Colon CancerDong-Hyun Kim, Yoon-Ok Ahnpp. 93-992002 Annual Report of the Korea Central Cancer Registry: Based on Registered Data from 139 HospitalsKyu-Won Jung, Young-Joo Won, Jae-Gahb Park, Hai-Rim Shinpp. 103-114Oxaliplatin with Biweekly, Low Dose Leucovorin and Bolus and Continuous Infusion 5-fluorouracil (Modified FOLFOX 4) as First-line Therapy for Patients with Metastatic Colorectal Cancer김성현, 김재석, 김효진, Kyoung Tae Kim, 권혁찬, Shin Ae Lee, 박종성pp. 115-120Impact of the New AJCC Staging System and Adjuvant Treatment in Rectal CancerChang Kil Jung, Shin Ae Lee, Min Ah Park, 이형식, 김성현, 권혁찬, 노미숙, 김재석, 김효진, 박기재, 최홍조pp. 121-127
원문 보기